ALKS

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 16

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,951

Underlying: Ordinary Shares · 685 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F13 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F13 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 15

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,803

Underlying: Ordinary Shares · 2,741 shares

Expires 2033-02-23

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F12 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 14

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,690

Underlying: Ordinary Shares · 523 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F11 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F11 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 13

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,344

Underlying: Ordinary Shares · 2,790 shares

Expires 2032-02-18

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F10 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 12

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,387

Underlying: Ordinary Shares · 380 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F9 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F9 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 11

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,221

Underlying: Ordinary Shares · 3,102 shares

Expires 2031-02-22

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F8 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 10

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,680

Underlying: Ordinary Shares · 91 shares

Expires not disclosed

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F6 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 9

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,287

Underlying: Ordinary Shares · 1,534 shares

Expires 2030-02-20

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 8

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,989

Underlying: Ordinary Shares · 1,489 shares

Expires 2029-02-21

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 7

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,759

Underlying: Ordinary Shares · 759 shares

Expires 2028-02-16

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 6

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,699

Underlying: Ordinary Shares · 699 shares

Expires 2027-02-17

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 5

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,899

Underlying: Ordinary Shares · 899 shares

Expires 2026-03-01

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 4

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,969

Underlying: Ordinary Shares · 469 shares

Expires 2025-02-26

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-004729 · form4.xml · derivative · entry 3

Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,599

Underlying: Ordinary Shares · 599 shares

Expires 2024-03-03

F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006174 · form4.xml · derivative · entry 13

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,630

Underlying: Ordinary Shares · 502 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F11 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F11 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-24-006174 · form4.xml · derivative · entry 12

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,522

Underlying: Ordinary Shares · 2,010 shares

Expires 2033-02-23

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F10 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-006174 · form4.xml · derivative · entry 11

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,064

Underlying: Ordinary Shares · 373 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F9 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F9 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-24-006174 · form4.xml · derivative · entry 10

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,674

Underlying: Ordinary Shares · 1,992 shares

Expires 2032-02-18

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F8 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-006174 · form4.xml · derivative · entry 9

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,217

Underlying: Ordinary Shares · 278 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-24-006174 · form4.xml · derivative · entry 8

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,028

Underlying: Ordinary Shares · 2,274 shares

Expires 2031-02-22

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-006174 · form4.xml · derivative · entry 7

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,901

Underlying: Ordinary Shares · 76 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-006174 · form4.xml · derivative · entry 6

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,212

Underlying: Ordinary Shares · 885 shares

Expires 2030-02-20

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-006174 · form4.xml · derivative · entry 5

Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,999

Underlying: Ordinary Shares · 999 shares

Expires 2029-06-05

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 18

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,310

Underlying: Ordinary Shares · 319 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F11 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F11 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 17

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,241

Underlying: Ordinary Shares · 1,279 shares

Expires 2033-02-23

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F10 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 16

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,345

Underlying: Ordinary Shares · 261 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F9 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F9 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 15

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,171

Underlying: Ordinary Shares · 1,394 shares

Expires 2032-02-18

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F8 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 14

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,309

Underlying: Ordinary Shares · 221 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 13

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,296

Underlying: Ordinary Shares · 1,809 shares

Expires 2031-02-22

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 12

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,461

Underlying: Ordinary Shares · 107 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 11

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,335

Underlying: Ordinary Shares · 1,790 shares

Expires 2030-02-20

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 10

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,411

Underlying: Ordinary Shares · 1,811 shares

Expires 2029-02-21

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 9

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,589

Underlying: Ordinary Shares · 1,089 shares

Expires 2028-02-16

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 8

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,999

Underlying: Ordinary Shares · 999 shares

Expires 2027-02-17

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 7

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,519

Underlying: Ordinary Shares · 1,519 shares

Expires 2026-02-28

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 6

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,879

Underlying: Ordinary Shares · 879 shares

Expires 2025-02-26

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 5

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,999

Underlying: Ordinary Shares · 999 shares

Expires 2024-03-03

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 11

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 290,570

Underlying: Ordinary Shares · 5,697 shares

Expires 2033-02-23

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 10

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,024

Underlying: Ordinary Shares · 5,980 shares

Expires 2032-02-18

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 9

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 349,030

Underlying: Ordinary Shares · 6,843 shares

Expires 2031-02-22

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F5 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 8

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 365,634

Underlying: Ordinary Shares · 7,168 shares

Expires 2030-02-20

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 7

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 389,844

Underlying: Ordinary Shares · 7,644 shares

Expires 2029-02-21

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: Shares underlying the stock option award shall not vest and become exercisable unless and until the closing price of an ordinary share of Alkermes plc, as reported by the Nasdaq Global Select Market or another national securities exchange on which Alkermes plc's ordinary shares are listed, is fifty U.S. Dollars (US$50.00) or higher for thirty (30) consecutive trading days during the term of the award (the "performance criteria"). Subject to achievement of the performance criteria, the shares underlying the stock option award shall vest in four equal annual installments commencing on 2/21/2020. This award expires ten years from the date of grant.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 6

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,419

Underlying: Ordinary Shares · 2,419 shares

Expires 2029-02-21

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 5

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,899

Underlying: Ordinary Shares · 5,899 shares

Expires 2028-02-16

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 4

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,999

Underlying: Ordinary Shares · 3,999 shares

Expires 2027-02-17

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 3

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 305,999

Underlying: Ordinary Shares · 5,999 shares

Expires 2026-02-28

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 2

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,999

Underlying: Ordinary Shares · 3,999 shares

Expires 2025-02-26

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-007137 · form4.xml · derivative · entry 1

POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 234,599

Underlying: Ordinary Shares · 4,599 shares

Expires 2024-03-03

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017710 · form4.xml · derivative · entry 7

Alva Emily Peterson · CIK 0001738422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 119 shares

Expires not disclosed

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

SEC source: 0001127602-24-017710 · form4.xml · derivative · entry 6

Alva Emily Peterson · CIK 0001738422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,986

Underlying: Ordinary Shares · 254 shares

Expires 2033-06-29

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.